c-suite

The healthcare AI reckoning

Taking ownership of the outcome will decide who leads in this reckoning

insight
September 21, 2026
9 min read

Author

Eugen-Rosenfeld

Eugen Rosenfeld

A CTO & a Solution Architect in Life Sciences at Nagarro. He has more than 20 years experience in different programming languages, technologies and business domains.

Executive note:

The issue is no longer whether healthcare AI works. The decisive question is whether the organization is ready to own what it deploys, especially when an AI-enabled decision or workflow fails in clinical practice.

A disproportional healthcare AI investment is still buying the appearance of progress: pilots, dashboards, vendor demonstrations, and visible innovation activity. The board-level risk is that these investments can create reputational exposure and operational distraction without changing care delivery, patient access, or clinical outcomes.

For directors and executive committees, the strategic shift is clear: AI leadership will be defined less by model sophistication and more by accountable operating capability. Governance, clinical ownership, lifecycle monitoring, and escalation discipline are not compliance overheads. They are the mechanisms that convert AI capability into safe, repeatable institutional advantage.

Much of healthcare’s AI spending is not yet changing care

It is worth naming something the industry often dresses up in press releases: a large share of healthcare AI spending funds the appearance of intelligence rather than its impact. Considerable investment flows toward glowing dashboards, early pilots, conference keynotes, and vendor logos on every workflow, while the actual practice of medicine changes very little. The model may be impressive, and the demo may dazzle the board, yet a clinician often sets it aside, because nothing in the real work has been redesigned to trust it.

The last decade proved that AI can work, and that question is now settled. Algorithms detect cancers earlier, forecast deterioration, and draft the documentation that exhausts clinicians. Capability is no longer the constraint, and treating it as the frontier is where much of the value is quietly lost. The organizations that win the demos are frequently not the ones changing outcomes. They are two very different groups, and confusing them is one of the most expensive mistakes in healthcare today.

Value in healthcare AI has rarely come from a better model. It comes from sustained, trusted, governed change in how work actually happens, and from the willingness to be accountable when that work touches a patient. The leaders of the next decade will not be defined by the smartest algorithms, but by the one thing that scales, which is a governed operating system that turns capability into consequence. Without it, even the most impressive investment struggles to reach the patient.

Disconnected pilots rarely become production

The pilot has become a comfortable place to pause. It is safe, fundable, produces a slide, and commits no one to much. That is precisely the challenge. A pilot that never threatens to change the org chart, the liability model, or the clinical workflow is not really a step toward production; it can, however, become a way of avoiding it. A portfolio of disconnected pilots is not yet a strategy. At best, perhaps, it is closer to a collection.

It helps to let go of the assumption that accuracy equals value. It does not, and holding onto it is why many pilots plateau. A diagnostic model at ninety-five percent sensitivity is a laboratory achievement, but an operational irrelevance if clinicians still re-verify every result, override it without documentation, or skip it when the department is overwhelmed. The metric improved while the medicine did not. What was purchased was a benchmark, not a transformation.

On the other hand, real value is concrete and reflects when decision latency falls, rework disappears, cases turn faster, and the patients the system has historically under-served, finally get seen. None of that comes from retraining the model. It comes from the organizational resolve to rebuild the workflow around the AI and to govern that change so it is safe, repeatable, and auditable. Polishing demos keeps a program busy; rebuilding the work is what moves it forward.

The real bottleneck is ownership, not technology

Ask why AI will not scale and the same familiar reasons appear: fragmented data, integration complexity, regulatory uncertainty, cybersecurity risk. These are real, and they can also be a convenient focus, because they are technical, fundable, and, importantly, blameless. The harder issue, and the one rarely named, is that inside most healthcare organizations, no single person owns the outcome when the AI is wrong.

Beneath many stalled programs sits the same unspoken tension. Clinicians and engineers do not fully agree on what "good enough" means. Operations and compliance do not agree on what counts as an "incident." The vendor owns the model, the provider owns the deployment, and when something goes wrong, responsibility becomes contested. Accountability is diffused, escalation paths are unclear, and trust fades the moment it is tested. This is less a data problem than a leadership gap.

An organization can buy better data and wait for cleaner regulation for years, and still not move a single system from pilot to production. Until someone can answer, without hesitation, who decides, who overrides, and who is accountable when the algorithm fails a patient, scaling remains out of reach. The bottleneck was never really in the stack, it has always been in the room where responsibility needs ownership.

"Responsible AI" needs a shared definition

Nearly every organization now commits to "responsible AI." The phrase has been repeated so often that its meaning has thinned. Ask five stakeholders what it means, and you will hear five different answers: manufacturers think of bias reduction, regulators of traceability, clinicians, of reliability in their own hands, patients, of disclosure, compliance, of an audit trail. While each cohort is right, but they all are fragments, on their own. When a fragment stands in for the whole principle, an organization can feel safe while remaining exposed.

Trust is not conferred by a transparency PDF, a one-time bias audit, or a compliance checkbox. It is earned through proof. Proof that the system works in your environment, on your data, for your population, not a vendor’s. Proof of who decided to deploy it and who answers for that decision. Proof that performance is monitored continuously, not admired once. And proof that a clinician or a patient can question the machine and receive a response. Anything less, is presentation rather than genuine responsibility.

The trust deficit in healthcare AI is not a minor issue to manage at the margins. It is fundamental. Medicine runs on trust, and an industry deploying systems it cannot fully explain, into decisions it cannot fully audit, is spending the only currency it has. Once that trust is spent, no algorithm easily wins it back.

Governance is the only real differentiator left

Nagarro-scribble

Here is a belief that quietly undermines success: that governance is the enemy of speed. Compliance and security are often called in at the end, handed a finished system, asked to approve it, and then blamed for the delay. This is not caution so much as a missed opportunity, and it is why the same organizations rebuild governance from scratch on every project and wonder why nothing scales.

Reverse the sequence, and governance becomes one of the fastest capabilities an organization owns. When compliance and security are co-designers from the first sketch, shaping requirements, architecture, and oversight, the organization stops negotiating controls at launch and starts inheriting them. Standards get reused, controls get repeated, and every new system launches faster than the last, because the hard questions were answered once, deliberately, instead of many times under pressure. Governance is not the brake. It is the accelerator that compounds.

This is the line that increasingly separates leaders from the rest. Those who lag treat governance as a tax on innovation. Leaders treat it as the shared language that lets clinicians, engineers, operators, and executives move together, each knowing how performance is monitored, what must be documented, who detects drift, and exactly how to raise the alarm. The differentiator of the next decade is not who has the best model, but who can operate one at scale without breaking trust. That is a governance capability, and few have built it.

Autonomy has arrived

It is time to stop treating autonomous AI as a distant horizon. It is already in the building. Generative tools that write and summarize gave way to predictive models that flag and forecast, and those have given way to systems that act, triggering alerts, adjusting interventions, and launching workflows with no human in the loop. This is not a roadmap item for a future committee. It is arriving in production while many organizations are still debating the ethics of a chatbot.

The moment AI acts instead of advises, the entire structure of accountability shifts, and that shift is often overlooked. A model that flags a high-risk patient leaves the clinician in command. A system that initiates the intervention has taken command. When that intervention is wrong, whether a missed contraindication or a subpopulation the model was never calibrated for, who carries the liability? Who is notified? Who reviews it before it reaches the next patient? When those answers do not exist, autonomy stops being innovation and becomes a risk the organization cannot responsibly accept.

Autonomy should be earned, not assumed. It is justified only where the evidence is strong, the oversight is real, and the accountability is clear, and it must be proportional to the harm it can cause. The governance that suffices for a recommendation is inadequate for an action, and the organizations that miss that distinction tend to learn it the hard way. The question is no longer whether to face autonomy, but whether you can address it deliberately, before events force the issue.

Four gates for a governed portfolio

Serious organizations do not manage AI as a loose collection of experiments. They manage it as a governed portfolio with the discipline to say no. Not every opportunity deserves funding. Not every model deserves deployment. Not every deployment deserves the same latitude. Four gates enforce that discipline, and treating them as optional is where the appearance of progress replaces the real thing.

The portfolio gate

Does this create real value, on data you actually have, inside a workflow that will actually absorb it, at a risk the organization can genuinely accept? If the honest answer is no, the project stops here, before a single engineer is assigned. Much wasted AI investment is funded because this gate was never built.

Discipline starts with the willingness to set ideas aside early.

The evidence gate

What is the model actually for, how does it perform against a real baseline, where is the bias, and what are the failure modes that are easy to leave unwritten?

The bar is not perfection, since perfection can become a stalling tactic. The bar is evidence sufficient for the specific context and honest about its own gaps. A deployment built on hope rather than proof is a liability with a launch date.

The deployment gate

Who owns this in production? How are overrides handled? What happens the day it fails? If those answers are vague, the system does not launch.

This is the gate that separates organizations ready-to-deploy AI from those that are not yet ready. An algorithm no one owns is not truly deployed is left unattended in a live workflow.

The lifecycle gate

Is it still performing? Has it drifted? Are clinicians still trusting it? Have new threats emerged? A model is not a monument; it decays, and a system approved once and never watched again, becomes a slow-motion incident.

This gate calls for intervention the moment safety or performance slips, because in medicine the alternative to vigilance is harm.

These are not bureaucratic checkpoints, and experiencing them that way usually means they were built wrong. They are the mechanism that makes speed safe by bringing the hard tradeoffs into the open. A project that does not clear the Portfolio Gate never wastes an engineering quarter. On a similar note, a model that does not clear deployment never becomes a headline. Lifecycle catches decay before it becomes a lawsuit. Discipline, it turns out, is faster than chaos, and far less costly.

Who owns this when it fails?

Scribble_n-DOMS

Accountability before deployment

Strip away the strategy decks and the vendor promises, and healthcare AI comes down to a single, demanding question: who owns this when it fails? Not when it demos, but when it fails a real patient, on a real day, in a real workflow. An organization that cannot answer that question, clearly and by name, is not yet ready to deploy AI. The concern is not that the technology is unsafe, but that the organization is not yet prepared for it.

Governance to make AI scale

This is not, in the end, a story about efficiency gains or productivity dashboards. It is a story about who thrives in the next decade of medicine and who becomes a cautionary example. The winners will not be the organizations with the most models or the largest AI teams, but the ones that built accountability before ambition, treated governance as a core competitive advantage rather than a compliance afterthought, and earned trust instead of assuming it.

Question the readiness, not AI

So the question is no longer whether AI works. That debate is over, and staying on it is how the wasted investment accumulates. The question that matters now is whether your organization is ready to own what it deploys. If it is, it can help define healthcare for a generation. If it is not, the pilots will keep glowing, the appearance of progress will continue, and eventually the audience, your patients, your clinicians, your regulators, may simply stop believing what they are shown.

The question is on the table. What is your answer?

FAQs:
The healthcare AI reckoning

Because too much investment is going into dashboards, pilots, demos, and vendor-led visibility, while the real practice of medicine often remains unchanged. The article argues that AI capability is no longer the main constraint; the real gap is whether care workflows have been redesigned to trust and use it.

Because pilots are often safe, fundable, and easy to showcase, but they do not force the hard changes required for scale. If a pilot does not challenge the clinical workflow, liability model, operating model, or ownership structure, it can become a way of delaying real transformation.

No. A highly accurate model can still be operationally irrelevant if clinicians re-check every result, override it without documentation, or skip it under pressure. Real value shows up when decision latency falls, rework reduces, cases move faster, and underserved patients are actually reached.

The bottleneck is ownership, not technology. Fragmented data, integration, regulation, and cybersecurity are real issues, but the harder question is: who owns the outcome when AI is wrong? Until leaders can answer who decides, who overrides, and who is accountable, scaling remains difficult.

It should mean proof, not presentation. Proof that the system works in the organization’s own environment, on its own data, for its own population. It also means clear accountability, continuous performance monitoring, and the ability for clinicians or patients to question the system and get a response.

Because governance is what turns AI from impressive capability into safe, repeatable operating change. The article argues that governance is not the brake; when compliance and security are involved from the start, standards are reused, controls are built in, and each new system can launch faster and more safely.

The four gates are: portfolio, evidence, deployment, and lifecycle. The portfolio gate asks whether the idea creates real value. The evidence gate checks performance, bias, and failure modes. The deployment gate confirms ownership and response when things go wrong. The lifecycle gate watches for drift, declining trust, new threats, and performance decay after launch.

Get in touch

The healthcare AI reckoning